Compare Baxter International Inc (BAX) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Innodata Inc — how do they compare? Baxter International Inc trades at $21.78 (market cap $11.26B), while Innodata Inc trades at $67.32 (market cap $2.19B). The key difference: Baxter International Inc is far larger — about 5.1× Innodata Inc's market cap, and Baxter International Inc pays a 0.92% dividend while Innodata Inc pays none. Which is the better fit depends on your goals.
| BAX | INOD | |
|---|---|---|
Market Cap | $11.26B | $2.19B |
Sector | Health | Technology |
52-Week High | $29.22 | $121.50 |
52-Week Low | $15.80 | $34.45 |
Enterprise Value | $18.93B | $2.08B |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
INOD trades at $68.12, up 0.47% today but down 33% over the past month. The stock shows strong fundamentals with revenue growth to $252M in 2025 and net income of $32M, while beating EPS estimates in recent quarters. Technical indicators signal a bearish trend, with resistance at $69 and support at $67. Recent news highlights AI-driven growth and a new CFO appointment.
Outlook remains positive due to AI demand and raised guidance, but high valuation (P/E 59.89) and customer concentration pose risks. Analyst consensus is bullish with a $130 price target, suggesting significant upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
